MK-8719, a Novel and Selective O-GlcNAcase Inhibitor That Reduces the Formation of Pathological Tau and Ameliorates Neurodegeneration in a Mouse Model of Tauopathy
Deposition of hyperphosphorylated and aggregated tau protein in the central [...]
Deposition of hyperphosphorylated and aggregated tau protein in the central [...]
Inhibition of O-GlcNAcase (OGA) has emerged as a promising therapeutic [...]
[18F]MK-8553 is a high affinity, selective OGA inhibitor with properties [...]
Advances Novel Tau-directed Strategy for Treating Neurodegenerative Disease Phase 1 [...]
Apr 18, 2016 – Alectos Therapeutics partner Merck, known as MSD [...]
Neurofibrillary tangles (NFTs) made up of aggregated tau protein have [...]
Vancouver, British Columbia (December 12, 2014) – Alectos Therapeutics Inc. [...]
Vancouver, British Columbia (November 16, 2012) – Alectos Therapeutics Inc. [...]
Collaboration Targets a Potential Non-Amyloid Approach to Treating Alzheimer’s Disease [...]